{"filings":[{"id":1057877,"accession_number":"0001104659-26-074090","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-06-15T20:40:42+00:00","items":["4.01","9.01"],"status":"ready","headline":"Coherus Oncology dismisses EY as auditor, appoints PwC effective June 12, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Ernst & Young as auditor effective June 12, 2026; no adverse opinions or disagreements in prior periods.","Audit committee selected PricewaterhouseCoopers as new auditor for FY 2026, subject to standard client acceptance.","A material weakness in internal control over inventory reconciliations reported for FY 2024 was remediated by FY 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759958,"accession_number":"0001104659-26-068615","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-06-01T12:30:30+00:00","items":["5.07"],"status":"ready","headline":"Coherus Oncology annual meeting results: directors elected, equity plan approved, option repricing narrowly passes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors Dennis M. Lanfear and Mats L. Wahlström re-elected with 82.5M and 81.2M votes for each, respectively.","Ratification of Ernst & Young as independent auditor approved by 121.1M votes for, 1.5M against.","Say-on-pay advisory vote on executive compensation passed with 73.3M for, 10.9M against, 4.8M abstain.","Stock option repricing proposal (Prop 4) approved in close vote: 46.0M for, 45.4M against, 0.4M abstain.","Increase in shares reserved under Amended 2014 Equity Plan approved: 59.5M for, 24.9M against, 4.6M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13325,"accession_number":"0001104659-26-058666","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-05-11T20:16:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Q1 LOQTORZI rev $11.8M (+61% YoY); net loss $36.9M; pipeline readouts mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LOQTORZI net revenue $11.8M in Q1 2026, up 61% YoY from $7.3M but down 5% from Q4 2025 $12.4M due to weather and seasonality.","GAAP net loss from continuing ops $36.9M ($(0.27) diluted EPS) vs $47.4M ($(0.41)) in Q1 2025; non-GAAP net loss $33.9M ($(0.25)).","Cash, cash equivalents and marketable securities $167.0M; Q1 equity offering of 32.89M shares raised net proceeds of $53.6M.","Casdozokitug Phase 2 1L HCC fully enrolled, first data readout expected mid-2026; tagmokitug combo studies with initial data mid-2026 and 2H 2026.","Q1 recorded highest new patient starts for LOQTORZI; average treatment duration growing; LOQTORZI remains only FDA-approved treatment for NPC."],"consensus_eps_estimate":-0.2788,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":12310000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104812,"accession_number":"0001104659-26-025293","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Oncology reports FY2025 net loss $183.1M; LOQTORZI revenue doubles to $40.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LOQTORZI net revenue $40.8M in 2025, more than double $19.1M in 2024; Q4 net revenue $12.4M up 11% QoQ.","Total debt reduced 90% from $480M to $38.8M during 2024-2025; year-end cash $172.1M.","FY2025 GAAP net loss $183.1M ($1.56 diluted) vs $215.4M loss in FY2024; non-GAAP loss $159.2M.","Pipeline: tagmokitug (CCR8) trials in HNSCC, GI, ESCC, CRC; casdozokitug (IL-27) Phase 2 in 1L uHCC; data readouts in mid-2026.","Equity financings: ~$7.9M net from Oct 2025 offering; ~$47.0M net from Feb 2026 public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104811,"accession_number":"0001104659-26-016378","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Coherus Oncology closes $47M public offering of 28.6M shares at $1.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 28.6M common shares at $1.75 public price; underwriters paid $1.645/share.","Net proceeds of ~$47.0M after underwriting discounts and commissions.","Underwriters have 30-day option to purchase up to 4.29M additional shares for over-allotments.","Directors, officers, and certain stockholders subject to 60-day lock-up agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104810,"accession_number":"0001104659-26-010065","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coherus enters Phase 1b combo trial with Janssen for tagmokitug in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical supply agreement with Janssen to evaluate tagmokitug (anti-CCR8) plus pasritamig in mCRPC Phase 1b.","Coherus sponsors trial; Janssen supplies pasritamig. Both retain full commercial rights to their compounds.","Tagmokitug is an investigational cytolytic monoclonal antibody targeting CCR8; study to start in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104809,"accession_number":"0001104659-26-006307","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Coherus Oncology files prospectus supplement for $64.9M ATM stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate offering price of up to $64,880,054 under Sales Agreement with TD Cowen.","Shares of common stock may be sold from time to time at then-prevailing market prices.","Legal opinion of Latham & Watkins on share validity filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104808,"accession_number":"0001104659-26-003117","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Oncology provides preliminary FY2025 revenue and cash at J.P. Morgan conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing furnishes preliminary unaudited net revenues for Q4 and FY2025 ended Dec 31, 2025.","Preliminary cash, cash equivalents and investments as of Dec 31, 2025 also disclosed.","Slide includes forward-looking projection of LOQTORZI revenue growth.","Actual final results may differ materially; independent auditor has not reviewed these preliminary figures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121091,"accession_number":"0001104659-25-111484","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Coherus recasts FY 2024/2023 financials for UDENYCA divestiture as discontinued operations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["UDENYCA sale to Intas completed April 11, 2025 for $483.4M upfront cash including $118.4M inventory.","Company eligible for two additional $37.5M earn-out payments.","Recast financials for FY 2024 and 2023 show biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations.","Recast is for incorporation into a Form S-3 registration statement filed Nov 13, 2025.","No other events after 2024 10-K filing are reflected except discontinued ops presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121090,"accession_number":"0001104659-25-107780","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Q3 LOQTORZI rev up 92% YoY to $11.2M; net loss narrows to $44.5M; CHS-114 enters colorectal cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.6M (up 90% YoY); LOQTORZI net revenue $11.2M (+12% QoQ, +92% YoY).","GAAP net loss from continuing ops $44.5M (-$0.38/sh) vs $47.6M (-$0.41/sh) prior year.","Non-GAAP net loss $38.9M (-$0.33/sh) vs $40.0M (-$0.35/sh); cash at $191.7M.","CHS-114 Phase 1b/2a enrolling in 4L+ colorectal cancer; initial data expected 2H 2026.","Casdozokitug Phase 2 in 1L HCC enrollment ongoing; first data readout mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":29424000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137720,"accession_number":"0001558370-25-011911","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coherus Oncology regains Nasdaq compliance after bid price shortfall","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 30, 2025, Coherus received a Nasdaq deficiency notice for bid price below $1.00 for 30 consecutive business days.","Company had 180 days, until December 29, 2025, to regain compliance.","On September 5, 2025, Nasdaq confirmed Coherus's closing price was $1.00 or greater for the requisite period.","Company is now in full compliance with all Nasdaq continued listing standards; matter is closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137719,"accession_number":"0001558370-25-010802","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Q2 LOQTORZI rev $10M (+36% QoQ); UDENYCA divestiture closed for $483M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LOQTORZI net revenue $10.0M in Q2 2025, up 36% from $7.3M in Q1 2025 and $3.8M in Q2 2024.","UDENYCA divestiture completed April 11, 2025; Coherus received $483.4M cash and is eligible for up to $75M milestones.","Used proceeds to repay substantially all $230M of 2026 Convertible Notes and buy out royalty rights for $47.7M.","Q2 2025 net loss from continuing ops $44.9M ($0.39 diluted loss) vs $54.9M ($0.48) YoY; non-GAAP net loss $39.0M.","Cash, cash equivalents and marketable securities $238M at June 30, 2025; CHS-114 and casdozokitug data readouts expected 1H 2026."],"consensus_eps_estimate":-0.3026,"consensus_eps_actual":2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":17853000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137718,"accession_number":"0001558370-25-009085","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Coherus Oncology receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 30, 2025, Nasdaq notified Coherus that its common stock closed below $1.00 for 30 consecutive business days.","Company has until December 29, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by deadline, Coherus may qualify for an additional 180-day period by transferring to Nasdaq Capital Market.","Failure to cure could lead to delisting; company intends to monitor bid price and evaluate options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155102,"accession_number":"0001104659-25-059351","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coherus Oncology annual meeting results: all director nominees elected, say-on-pay and ESPP amendment approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Jill O'Donnell-Tormey, Michael Ryan, and Ali J. Satvat as Class II directors with 32.8M, 32.7M, and 27.8M votes for, respectively.","Ratified Ernst & Young as independent auditor for FY 2025 with 74.5M votes for, 777K against, 306K abstain.","Advisory say-on-pay resolution approved with 19.2M for, 16.2M against, 3.6M abstain; broker non-votes 36.7M.","Amendment to 2014 Employee Stock Purchase Plan approved with 27.7M for, 7.6M against, 3.6M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155101,"accession_number":"0001558370-25-008294","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Coherus BioSciences renames to Coherus Oncology, sharpens focus on cancer immunotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Coherus Oncology, Inc. effective May 29, 2025; stock ticker CHRS unchanged.","Company now exclusively focused on proprietary immuno-oncology medicines; pipeline includes LOQTORZI, CHS-114, and casdozokitug.","LOQTORZI is a next-gen PD-1 inhibitor approved for nasopharyngeal carcinoma; CHS-114 is a CCR8 antibody in Phase 1b.","Casdozokitug, an IL-27 antagonist, is in a randomized Phase 2 study for first-line advanced metastatic HCC.","Board and scientific advisors include leaders from Cancer Research Institute, MSKCC, and HHMI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155100,"accession_number":"0001558370-25-007410","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Q1 2025: LOQTORZI rev $7.3M, net loss $47.4M; UDENYCA divestiture closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Continuing ops net loss $47.4M ($0.41 diluted); non-GAAP net loss $40.9M ($0.35).","LOQTORZI net revenue $7.3M, patient demand grew >15% vs Q4 2024.","UDENYCA divestiture closed April 2025 for upfront $483.4M, total up to $558.4M.","CHS-114 Phase 1b shows confirmed partial response in PD-1 refractory HNSCC; proof of mechanism.","Casdozokitug Phase 2 randomized trial in 1L HCC enrolling; data readout expected 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":7599000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155099,"accession_number":"0001558370-25-005554","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mark Stolper to leave board at 2025 annual meeting; board rebalanced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark D. Stolper notified Board he will not stand for re-election at 2025 annual meeting; departure not due to any disagreement.","Stolper will serve until election of directors at 2025 Annual Meeting, then expected to consult through Dec 31, 2026.","Board decreased authorized directors from 10 to 9, effective upon Stolper's departure.","Rita A. Karachun reclassified from Class II to Class I; Michael Ryan from Class III to Class II to balance board classes.","Board now has three Class I, four Class II, and three Class III directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155098,"accession_number":"0001558370-25-005157","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Coherus announces CCO Paul Reider resignation effective April 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Reider resigned as CCO and employee effective April 30, 2025, to pursue other opportunities.","Resignation follows completion of UDENYCA franchise divestiture; not due to any disagreement.","Severance includes 12 months base salary and COBRA reimbursement through Dec 31, 2026.","Vesting extended for unvested equity through Dec 31, 2026; option exercise period extended.","Reider will advise executive leadership on a part-time basis until April 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155097,"accession_number":"0001558370-25-004746","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Coherus completes UDENYCA divestiture to Intas for $483.4M upfront; pivots to oncology","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of UDENYCA franchise on April 11, 2025; receives $483.4M cash including $118.4M for inventory.","Eligible for two milestone payments up to $75M total if net sales thresholds met through 2027.","Pro forma cash balance post-close ~$250M; cash runway extended over two years into 2027.","Plans to use proceeds to repurchase $230M of 1.500% Convertible Notes due 2026.","Focus shifts to LOQTORZI, casdozokitug, and CHS-114 novel oncology pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155096,"accession_number":"0001558370-25-004264","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Coherus to repurchase $170M of convertible notes, conditional on UDENYCA sale close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Coherus agreed to repurchase ~$170M aggregate principal of its 1.500% Convertible Notes due 2026 at 100% par plus accrued interest.","Repurchases conditioned on closing of UDENYCA franchise divestiture to Intas Pharmaceuticals, expected early Q2 2025.","After repurchase, ~$60M of notes remain; Coherus plans a repurchase offer for those notes post-close.","Holders representing a majority of outstanding notes consented to indenture amendments permitting the UDENYCA divestiture.","Amendments executed via supplemental indenture dated March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173621,"accession_number":"0001558370-25-002842","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coherus stockholders approve UDENYCA sale to Intas Pharmaceuticals","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders voted 70,989,067 FOR, 968,989 AGAINST, 621,431 ABSTAIN; majority threshold was 57,945,094.","Approval clears key milestone for divestiture of UDENYCA (pegfilgrastim-cbqv) franchise under Dec 2, 2024 Asset Purchase Agreement.","Special Meeting held virtually on March 11, 2025; 115,890,186 shares outstanding as of Jan 27, 2025 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173620,"accession_number":"0001558370-25-002595","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus swings to FY 2024 net income of $28.5M; UDENYCA divestiture on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 net income $28.5M ($0.25 diluted EPS) vs net loss $237.9M in FY 2023; revenue $267M, +4%.","UDENYCA net revenue $206M (+62% YoY); LOQTORZI Q4 revenue $7.5M, +29% QoQ.","Non-GAAP net loss $86.3M ($0.75 loss per share) improved from $186.2M in FY 2023.","UDENYCA divestiture up to $558.4M; shareholder vote March 11, expected close late Q1/early Q2 2025.","Post-divestiture projected cash ~$250M, cash runway >2 years; headcount reduction ~30%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173619,"accession_number":"0001558370-25-002117","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coherus supplements proxy for UDENYCA sale; discloses JPMorgan valuation & cash flow projections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four shareholder complaints filed in NYC Supreme Court alleging proxy deficiencies; company denies merit.","Voluntarily adds JPMorgan's selected transaction analysis: implied consideration ~$530M (base plus risk-adjusted earnout).","Discloses UDENYCA unlevered free cash flow: $51M in 2025E, rising to $105M by 2029E, with revenue $186M in 2025E.","Special meeting to approve sale to Intas Pharmaceuticals remains scheduled for March 11, 2025.","Company believes no supplemental disclosures are legally required but provides them to avoid litigation delay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173618,"accession_number":"0001558370-25-000167","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Coherus provides preliminary Q4/FY2024 revenue and cash; UDENYCA allocated due to strong demand","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary unaudited net revenues for Q4 and FY2024 presented at J.P. Morgan Healthcare Conference.","Cash, cash equivalents and investments as of Dec 31, 2024 disclosed; final results may materially differ.","All three presentations of UDENYCA temporarily allocated due to strong demand in Q4 2024 and into Q1 2025.","Financial closing procedures not yet complete; independent auditor has not reviewed these preliminary results."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":266960000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190594,"accession_number":"0001558370-24-016012","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kimberly J. Tzoumakas resigns from Coherus board effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kimberly J. Tzoumakas resigned from Coherus BioSciences Board, effective December 31, 2024.","Resignation was not due to any disagreement with the Company's operations, policies, or practices.","No replacement director has been announced as of the filing date.","The Company thanked Ms. Tzoumakas for her contributions during her tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190593,"accession_number":"0001104659-24-124881","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Coherus to divest UDENYCA franchise to Intas for up to $558.4M; plans to repay convertible notes","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash $483.4M (subject to inventory adj.) plus up to $75M in net sales milestones ($37.5M each at $300M and $350M thresholds).","Proceeds to fully repay $230M 1.5% convertible notes due April 2026 and buy out $49.1M royalty obligation on UDENYCA.","Post-close cash runway over 2 years; focus shifts to immuno-oncology pipeline (LOQTORZI, casdozokitug, CHS-114).","Transaction requires shareholder approval, HSR, CFIUS; expected close Q1 2025; board unanimously recommends.","Coherus to provide Q4 2024 sales and Q1 2025 cash guidance in early January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190592,"accession_number":"0001558370-24-014642","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Q3 revenue $70.8M, UDENYCA up 30% QoQ; net loss narrows to $10.8M from $39.6M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $70.8M; UDENYCA $66.1M (+30% QoQ, +100% YoY); LOQTORZI $5.8M (+54% QoQ).","Net loss $10.8M ($0.09 loss per share) vs $39.6M loss in Q3 2023; non-GAAP net loss $1.7M.","UDENYCA supply: CMO resumes production; backlog ~120k units expected by year-end; new CMO testing, commercial supply Q1 2025.","Pipeline: Phase 2 HCC study of casdozokitug+toripalimab+bevacizumab opening; CHS-114 Phase 1 data expected H1 2025.","Gross profit improved on divested products (CIMERLI, YUSIMRY); SG&A down $13.5M YoY on lower headcount."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":212816000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207088,"accession_number":"0001558370-24-012783","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Coherus warns of temporary UDENYCA supply interruption due to packaging CMO constraints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third-party CMO over-commitments cause labeling/packaging delay; API and drug product unaffected.","Channel supply projected depleted by mid-Oct; manufacturing to resume mid-Oct, product availability early Nov.","Company secures second packaging CMO; commercial supply expected Q1 2025, more than doubling capacity.","Since 2021, invested >$30M across supply chain; expects UDENYCA production cost to drop ~1/3 from current levels.","Reaffirms combined 2024 R&D and SG&A expense guidance of $250-265M, including ~$40M stock-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207087,"accession_number":"0001558370-24-011618","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Coherus Q2 net loss narrows to $12.9M; UDENYCA sales up 60% YoY; appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net revenue $65.0M (+11% YoY); net loss $12.9M ($0.11 loss per share) vs $42.9M loss in Q2 2023.","UDENYCA net sales $50.9M (+60% YoY); market share 29% (+4 pts QoQ). LOQTORZI net sales $3.8M in first launch quarter.","Divestitures of CIMERLI and YUSIMRY generated $177.7M gain in H1 2024; repaid $250M term loan, replaced with $38.7M facility.","Pipeline: CHS-114 expansion cohorts enrolling; CHS-1000 IND cleared; casdozokitug Phase 2 planned Q4 2024.","Bryan McMichael appointed CFO, effective Aug 1, 2024; base salary $476K, 50% target bonus, 75,000 stock option grant."],"consensus_eps_estimate":null,"consensus_eps_actual":0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":142042000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207086,"accession_number":"0001558370-24-009650","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Coherus licenses toripalimab rights in Canada to Apotex for $6.25M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $6.25M USD; up to $51.5M CAD in regulatory and sales milestones.","Apotex to pay low double-digit percentage of net sales; Coherus pays Junshi under existing collaboration.","License term: 10 years after first commercial sale, with option to extend for another 10 years.","Apotex may terminate for any reason after notice; agreement ends if Coherus-Junshi collaboration terminates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224418,"accession_number":"0001558370-24-009526","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Coherus sells YUSIMRY (adalimumab-aqvh) to HKF for $40M upfront cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront all-cash consideration of $40M; closing occurred June 26, 2024.","HKF's subsidiary Meitheal will commercialize YUSIMRY in the U.S.","HKF assumes $17M in inventory purchase commitments; Coherus retains certain excluded assets/liabilities.","Divestiture aligns with Coherus' strategic focus on oncology; proceeds to bolster cash position.","Coherus retains oncology assets including LOQTORZI, UDENYCA franchise, and immuno-oncology pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224417,"accession_number":"0001558370-24-008918","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Coherus BioSciences appoints Rita A. Karachun to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 10 to 11; Karachun appointed as Class II director effective May 31, 2024.","To serve on Audit Committee; received option for 168,000 shares vesting over 3 years.","Previously SVP & Global Controller at Merck & Co. (2014-2023).","Annual cash retainer of $60k for board and audit committee service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224416,"accession_number":"0001558370-24-008898","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Coherus stockholders elect directors, approve say-on-pay and equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class I directors: Newcomer (48.3M for), Newton (47.2M for), Tzoumakas (46.1M for).","Ratified Ernst & Young as auditor for FY2024 with 79.8M for, 552K against.","Advisory say-on-pay approved (40.3M for, 16.5M against, 1.8M abstain).","Restated 2014 Equity Incentive Award Plan approved (37.6M for, 18.9M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224413,"accession_number":"0001558370-24-008542","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K/A","filed_at":"2024-05-21T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Coherus discloses terms of senior secured term loan and revenue participation sale","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Filed Loan Agreement: senior secured term loan from multiple lenders, interest at Term SOFR + margin, maturity date TBD.","Loan includes makewhole amount for prepayment within first year and prepayment premium.","Filed Revenue Purchase and Sale Agreement with Coduet Royalty Holdings LLC; terms not disclosed.","Guarantors include Coherus Intermediate, Intekrin Therapeutics, Surface Oncology, Coherus Oncology Supportive Care.","Minimum liquidity covenant required; specific amount not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224415,"accession_number":"0001558370-24-007622","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Q1 revenue $77.1M, net income $102.9M; UDENYCA +63% YoY; LOQTORZI launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $77.1M in Q1 2024 vs $32.4M in Q1 2023; GAAP net income $102.9M ($0.83 diluted EPS) vs net loss of $75.7M.","UDENYCA net sales $42.7M, up 18% QoQ and 63% YoY; LOQTORZI launch sales $2.0M; CIMERLI divested for $187.8M cash.","Non-GAAP net loss $35.8M (-$0.32 per share), improved from non-GAAP net loss $59.5M in Q1 2023.","New debt and royalty financing replaces $75M term loan; debt maturity extended to May 2029.","Entered partnership with CRI and ENB Therapeutics to study toripalimab in ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":77063000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224414,"accession_number":"0001558370-24-007468","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Coherus enters $38.7M term loan and $37.5M royalty sale to repay $75M prior debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $38.7M senior secured term loan at 8.00% + 3M SOFR; matures May 8, 2029; interest-only quarterly.","Proceeds used to repay $75M prior loan from BioPharma Credit; prior loan terminated with prepayment fee and make-whole.","Entered royalty sale of mid-single-digit % of U.S. net sales of UDENYCA and LOQTORZI for $37.5M; buyer receives up to 2.25x purchase price.","Loan prepayment penalties: 10% in year 2, 5% in year 3, 0% after year 3; default interest adds 4%.","Loan secured by substantially all assets; financial covenant requires maintaining certain cash levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243726,"accession_number":"0001558370-24-003110","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus reports FY2023 revenue $257.2M, divests CIMERLI to Sandoz for $170M, plans debt paydown","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net revenue $91.5M (+102% YoY); FY2023 $257.2M (+22% YoY); net loss $79.7M Q4, $237.9M FY.","Closed ophthalmology divestiture to Sandoz on March 1 for $170M upfront plus $17.8M inventory/assets.","Plans to prepay $175M of $250M term loan by April 1, cutting interest ~70%; workforce reduction of 30%.","Launched LOQTORZI (NPC) and UDENYCA ONBODY in Q1 2024; UDENYCA market share 26% as of March 1.","2024 guidance: SG&A+R&D $250-265M (down from $301.5M in 2023); annual cost savings >$25M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243725,"accession_number":"0001558370-24-002306","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["2.01","2.04","1.01","8.01","9.01"],"status":"ready","headline":"Coherus completes CIMERLI ophthalmology sale to Sandoz for $170M cash; repays $175M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of CIMERLI franchise to Sandoz for upfront $170M cash plus $17.8M for inventory and prepaid manufacturing assets.","Proceeds used to partially repay $175M of $250M term loan principal on or before April 1, 2024, plus $6.8M premium and makewhole.","Transaction sharpens strategic focus on oncology; CIMERLI BLA, sales team, and commercial software transferred.","Pro forma net loss for nine months ended Sep 30, 2023 would have been $196M versus historical $158M; loss per share $1.97 vs $1.79.","Cash and equivalents pro forma $77.7M after debt paydown and disposition adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243724,"accession_number":"0001558370-24-001542","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Coherus Biosciences appoints Georgia Erbez to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 directors; Erbez appointed as Class III director until 2026 annual meeting.","Erbez also named to audit committee; has served as Managing Director of Axiom Financial Partners since 2014.","Non-employee director: receives $50,000 annual cash retainer and option to purchase 54,000 shares vesting over 3 years.","Previous roles include CFO of Harpoon Therapeutics and COO of Walking Fish Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243723,"accession_number":"0001558370-24-000740","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Coherus amends loan with Pharmakon; to prepay $175M, reduce interest ~70%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["After closing ophthalmology divestiture to Sandoz, Coherus will prepay $175M of $250M loan principal, leaving $75M residual.","Revenue covenant reduced to $125M under amended loan agreement with Pharmakon Advisors.","Projected annual interest expense on term loan reduced by approximately 70%.","Prepayment expected in Q2 2024; strengthens balance sheet for oncology growth.","Amendment also provides consent and releases collateral tied to Sandoz transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243722,"accession_number":"0001193125-24-011700","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Coherus divests CIMERLI ophthalmology franchise to Sandoz for $170M upfront cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Divestiture of CIMERLI (ranibizumab-eqrn) and supporting commercial infrastructure to Sandoz.","Total upfront cash consideration $170M plus value of CIMERLI product inventory and working capital adjustments.","Coherus intends to use proceeds to pay down debt, reduce interest costs, and focus on oncology (UDENYCA, LOQTORZI, pipeline).","Closing expected first half 2024, subject to HSR antitrust waiting period expiration or termination.","Coherus reduces headcount and overhead; J.P. Morgan and Latham & Watkins advised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243721,"accession_number":"0001558370-24-000166","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus presents preliminary unaudited FY2023 revenue at JPM conference; no specifics in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary unaudited FY2023 revenue presented at 42nd Annual J.P. Morgan Healthcare Conference.","Financial closing procedures not yet complete; final results may materially differ.","Independent registered public accounting firm has not reviewed the preliminary data.","Filing includes cautionary note about the preliminary nature of the results."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":257244000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243720,"accession_number":"0001558370-24-000165","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coherus terminates TIGIT program collaboration with Junshi Biosciences after portfolio review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delivered notice of termination on January 10, 2024 for the TIGIT Program (CHS-006).","Decision follows Surface Oncology acquisition and portfolio prioritization; agreement remains effective for LOQTORZI (toripalimab-tpzi).","Coherus will continue to support patients in ongoing CHS-006 studies (NCT05061628, NCT05757492).","Company believes termination is in its best interests; wind-down expected over coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261132,"accession_number":"0001104659-23-129338","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Coherus receives FDA approval for UDENYCA ONBODY on-body injector","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved UDENYCA ONBODY on December 26, 2023, a pegfilgrastim biosimilar to reduce febrile neutropenia after chemotherapy.","Product includes indicator light, auditive signal, and automatic needle retraction to confirm dose and reduce needlestick risk.","Commercial launch planned for Q1 2024.","Approval supported by pharmacokinetic/pharmacodynamic bioequivalence and adhesive performance data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261131,"accession_number":"0001558370-23-019713","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Coherus CFO Stilwell resigns; EVP McMichael named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McDavid Stilwell resigned as CFO and Principal Financial Officer, effective Dec 31, 2023, to pursue other opportunities.","Bryan McMichael appointed Interim CFO and Principal Financial Officer, effective Dec 8, 2023.","McMichael continues as EVP, Accounting, Corporate Controller and Principal Accounting Officer; previously at Gilead Sciences.","No compensatory changes or grants in connection with the interim appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261130,"accession_number":"0001558370-23-019636","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Coherus Biosciences CFO McDavid Stilwell resigns effective Dec 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO McDavid Stilwell resigns to pursue other opportunities; effective Dec 31, 2023.","Resignation not related to any disagreement with company's operations, financials, or policies.","No successor named yet; Stilwell may provide transitional services by mutual agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261129,"accession_number":"0001558370-23-019328","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Coherus sets LOQTORZI price at $8,892.03/vial for NPC treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for first-line and later-line metastatic NPC.","Coherus announced wholesale acquisition cost of $8,892.03 per single-use vial on Nov 27.","LOQTORZI is co-administered with cisplatin and gemcitabine in first-line setting.","This pricing establishes commercial launch basis for the PD-1 inhibitor in NPC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261124,"accession_number":"0001193125-23-275207","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K/A","filed_at":"2023-11-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Coherus completes Surface Oncology acquisition, files Surface's financials on 8-K/A","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Sep 8, 2023; Surface became wholly owned subsidiary after two-step merger.","Unaudited condensed financial statements of Surface for H1 2023 and 2022 now filed on this amendment.","Financial statements incorporated from Surface's Q2 2023 10-Q filed Aug 2, 2023.","Original 8-K filed Sep 8, 2023 reported the closing; this amendment adds required financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261128,"accession_number":"0001558370-23-017778","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Coherus Q3 net revenue $74.6M (+27% QoQ); net loss narrows to $39.6M; LOQTORZI approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 net revenue $74.6M, up 27% from Q2; net loss $39.6M ($0.41/sh) vs $86.7M ($1.11/sh) in Q3 2022.","CIMERLI net sales $40.0M (+50% QoQ); UDENYCA net sales $33.0M (+4% QoQ); YUSIMRY launched with $1.4M Q3 sales.","FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for nasopharyngeal carcinoma; commercial launch expected Q1 2024.","Closed Surface Oncology acquisition on Sep 8, adding clinical-stage anti-IL-27 and anti-CCR8 I-O pipeline assets.","UDENYCA ONBODY BLA resubmitted Oct 4; potential approval late 2023 or early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":165720000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261123,"accession_number":"0001193125-23-270796","cik":1512762,"company_name":"Coherus Oncology, Inc.","ticker":"CHRS","form_type":"8-K/A","filed_at":"2023-11-06T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Coherus files Surface Oncology audited financials: $63.6M net loss in 2022, going concern noted","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Surface Oncology reported net loss of $63.6M for 2022 on $30M revenue; accumulated deficit reached $204.3M.","Auditor raised substantial doubt about Surface's ability to continue as a going concern due to operating losses, debt repayment, and lease termination.","For 2020, Surface had net income of $59.3M and revenue of $126.2M from GSK license, but losses resumed thereafter.","Pro forma combined financial statements as of June 30, 2023 reflect the merger with Coherus, completed September 8, 2023.","Surface paused internal clinical development of SRF617 and reduced workforce by ~20% in Q4 2022, incurring $4M restructuring charge."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":253741094.41867468,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-06T23:59:59+00:00|261123"}